+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 22 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are comparing the short-term effectiveness and safety of selective laser trabeculoplasty SLT against 0.005% latanoprost eye drops for lowering eye pressure in patients newly diagnosed with early to moderate primary open-angle glaucoma POAG or ocular hypertension OHT. The study aims to determine if SLT is as effective and safe as latanoprost eye drops when used as the first treatment option. It also evaluates how each treatment affects patients quality of life. Participants will be randomly assigned to one of two groups. One group will use 0.005% latanoprost eye drops every night for three months, while the other will receive a one-time SLT laser treatment. Intraocular pressure will be checked regularly over the three-month period, and any side effects will be recorded during follow-up visits. The study will take place at the Lagos State University Teaching Hospitals glaucoma clinic and will involve monitoring eye pressure changes over three months. Participants will have regular assessments to track treatment effects, side effects, and quality of life. The trial is designed to provide detailed information about how these treatments perform as initial therapy for glaucoma or ocular hypertension.

Age: 18Years - 90YearsAll GendersPhase Not Applicable
1 location
W

Actively Recruiting

This research aims to improve how appendicitis, a common emergency surgery condition, is managed worldwide by studying different emergency care systems. Appendicitis requires quick diagnosis and treatment to avoid complications. Using appendicitis as a marker, the study looks at access, quality, and efficiency across hospitals in various countries, including low- and middle-income regions, to find ways to enhance emergency surgical care. The study collects data from about 500 hospitals globally between February and May 2025, focusing on patients undergoing appendicectomy using any surgical method, including open, laparoscopic, or robotic approaches. Hospitals will record information for consecutive patients over 14-day periods. The study includes two sub-studies one on sustainability and waste management in operating rooms and another on the financial impact of surgery on patients, especially in resource-limited settings. Participants will have their care observed through routine health records without extra follow-up visits. Researchers will measure key factors such as time from symptoms to surgical assessment, rates of minimally invasive surgery, complications within 30 days, and hospital stay length. This data will help identify gaps and guide improvements in emergency surgical care worldwide, aiming to make treatment safer, faster, and more affordable.

All AgesAll Genders
7 locations
E

Actively Recruiting

This research aims to evaluate the safety and effects of a new medicine called etavopivat in treating pediatric patients with sickle cell disease who are at increased risk for primary stroke. Participants will be grouped based on their transcranial doppler TCD ultrasound results and whether they are taking hydroxyurea, a medication already used for this condition. The study focuses on those with conditional or abnormal TCD results, with the study doctor determining the classification. This is a phase 2, open-label trial designed to assess etavopivats activity on blood flow velocities in key brain arteries. Participants will receive 400 mg of etavopivat orally once daily for a 52-week treatment period. This dose consists of two 200 mg tablets taken with water, with or without food. Participants are divided into two cohorts one receiving etavopivat alone, and another receiving etavopivat in combination with a stable dose of hydroxyurea. After the initial treatment period, there is an optional 48-week extension to further evaluate the safety of etavopivat in pediatric patients. At the studys conclusion, participants may have the option to join a separate study to continue etavopivat treatment. Throughout the study, participants will visit the clinic frequently for assessments, including transcranial doppler ultrasound measurements to track blood flow velocities at various time points. Researchers will monitor changes in the highest time-averaged maximum mean velocities TAMMV in the internal carotid and middle cerebral arteries, as well as the incidence of changes in TCD velocity categories. Safety and treatment effects will be closely observed during both the primary and optional extension periods, with total participation lasting up to 100 weeks if the extension is chosen.

Age: 12Years - 16YearsAll GendersPhase 2
9 locations
S

Actively Recruiting

Researchers are studying osivelotor, an oral drug, in adults and adolescents with sickle cell disease SCD. This Phase 23 trial aims to evaluate the safety, tolerability, effectiveness, and how the body processes the drug. The study includes participants with specific SCD types and looks to find the best dose while also comparing the drug against a placebo over 48 weeks. A long-term extension will assess ongoing safety and blood response. The study has three parts. Part A tested safety and dose in adults to find the optimal dose. Part B compares osivelotor to placebo in adults and adolescents over 48 weeks, with adults receiving a loading dose of 300 mg daily for 7 days then 150 mg daily, while adolescent doses will be defined later. An open-label extension allows participants who completed Part B to take osivelotor for up to two years or until it becomes commercially available. Participants will undergo screening to confirm eligibility, including stable hemoglobin levels and SCD history. During the trial, participants receive study medication or placebo and attend regular visits for monitoring. Researchers will assess safety, blood characteristics, and vaso-occlusive crisis events. The study includes careful monitoring of adverse events and blood tests, with a total participation period that may last up to two years for those in the extension phase.

Age: 12Years +All GendersPhase 2Phase 3
80 locations
L

Actively Recruiting

Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.

Age: 2Years +All GendersPhase 3
107 locations
G

Actively Recruiting

Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.

Age: 12Years +All GendersPhase 3
175 locations
E

Actively Recruiting

Researchers are evaluating the pharmacokinetics and safety of etavopivat in children with sickle cell disease SCD. The study involves pediatric participants ranging in age from 6 months to less than 18 years and is designed as a phase 2, open-label, single-group study. Participants will be enrolled in age-based cohorts starting with the oldest group, with younger groups added sequentially after reviewing safety and pharmacokinetic data from prior cohorts. Participants will receive oral etavopivat once daily as either tablets or granules. The treatment includes a primary period lasting 24 weeks, followed by a 72-week extension period to further assess long-term safety and pharmacokinetics. The total study duration for each participant is approximately 96 weeks. Four age cohorts are studied 12 to less than 18 years, 6 to less than 12 years, 2 to less than 6 years, and 6 months to less than 2 years. Throughout the study, participants will be closely monitored with blood tests measuring etavopivat levels and hemoglobin changes, assessments of vaso-occlusive crisis frequency, and fatigue scales. Safety is evaluated by tracking adverse events, dose changes, and treatment interruptions. Transcranial Doppler ultrasound is used to assess cerebral blood flow at scheduled visits. The study includes frequent evaluations during both treatment periods to understand the drugs effects and safety in this young population.

Age: 6Months - 18YearsAll GendersPhase 2
18 locations
E

Actively Recruiting

This research aims to evaluate cancer treatment based on HER2 status in Nigerian women with HER2-positive breast cancer. The study focuses on assessing the safety and effectiveness of anti-HER2 therapy given before and after surgery. It specifically looks at how well the treatment works and its safety when combined with chemotherapy. Participants will receive a combination of trastuzumab and pertuzumab PHESGO along with chemotherapy. Initially, all participants get docetaxel injections for 4-6 cycles while receiving trastuzumab and pertuzumab as subcutaneous injections for 52 weeks. Depending on how their cancer responds after this phase, some will undergo surgery and continue receiving pertuzumab and trastuzumab for 36 weeks, possibly with hormone therapy such as tamoxifen, letrozole, or goserelin. Others with less favorable responses will receive trastuzumab emtansine intravenously plus standard chemotherapy. During the study, participants will have regular assessments including ultrasounds to monitor tumor response, laboratory tests, and echocardiograms to check heart function. Researchers will track outcomes like pathological complete response, adverse events, quality of life, and survival over 10 years. The study involves continuous monitoring and follow-up to evaluate treatment effects and safety throughout this period.

Age: 18Years +FEMALEPhase 2
4 locations
D

Actively Recruiting

Healthy Volunteer

This research aims to assess whether various types of digital health communication can increase parents intention to vaccinate their daughters aged 9 to 14 years against human papillomavirus HPV in Nigeria. HPV vaccination is important for preventing cervical cancer, but vaccination rates remain low due to parental hesitancy, misinformation, and limited engagement with existing health materials. This trial is designed as a randomized controlled study focusing on scalable digital approaches. Participants, who are parents or primary caregivers of unvaccinated girls aged 9 to 14, will be randomly assigned to one of five groups. These groups receive different digital content a motivational interviewing-style chatbot, an interactive game to combat vaccine misinformation, short educational videos about HPV vaccination, standard infographics from a national health agency, or unrelated health content about menstruation. All content is delivered online, and participants complete baseline and follow-up surveys. During the study, parents will report their intention to vaccinate immediately and one week after viewing the assigned content, with additional follow-ups at six months to measure vaccine uptake and other knowledge and attitude outcomes. Researchers will evaluate changes in HPV vaccine knowledge, perceptions of safety, willingness to recommend vaccination, and actual vaccine uptake. The total study period extends to December 2026, with data collected digitally and analyzed under an intention-to-treat approach.

Age: 27Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

This research aims to find out if wearable sensors can help detect early signs of health problems after major surgery. The study focuses on surgical patients who might become critically ill after their operations. It evaluates if continuous monitoring of vital signs like heart rate and oxygen levels using wearable devices can identify patient deterioration sooner than standard care. The study is observational and involves multiple countries including Benin, Ghana, Guatemala, India, Mexico, Nigeria, Rwanda, and the United Kingdom. Participants will wear wireless sensors on their chest and fingers before, during, and after surgery for up to 10 days. These sensors record vital signs continuously but do not affect patient care, as clinical teams will not access the data during the study. The first two stages of the study involved testing device usability with healthcare workers, while this third stage collects real-time sensor and clinical event data to explore links between physiological changes and patient complications. During the study, participants will have their vital signs monitored with wearable devices while also receiving standard clinical observations. Researchers will collect cardiovascular, respiratory, and temperature data alongside routine care information and clinical events. They will follow patients for 10 days of monitoring plus an additional 30-day follow-up to observe complications. The goal is to gather data to help design future algorithms for early detection of postoperative problems without changing current treatment practices.

Age: 18Years +All Genders
17 locations

1-10 of 22

1